Drugs Made In America Acquisition Corp. Units (DMAAU) — Cash Flow Quality Index

Latest as of December 2025: -0.59x

Drugs Made In America Acquisition Corp. Units (DMAAU) has a Cash Flow Quality Index of -0.59x as of December 2025. Operating cash flow of $-125.18K is below net income of $212.96K, suggesting accrual-heavy earnings not yet converted to cash. Explore Drugs Made In America Acquisition Corp. (DMAAU) cash flow conversion to assess how effectively this company generates cash.

Cash Flow Quality Index

-0.59x
Operating CF / Net Income

Operating Cash Flow

$-125.18K
USD

Net Income

$212.96K
USD

Data as of

Dec 2025
Most recent filing

Drugs Made In America Acquisition Corp. Units Cash Flow Quality Index (2025–2025)

Historical Cash Flow Quality Index for Drugs Made In America Acquisition Corp. Units across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Drugs Made In America Acquisition Corp. total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for Drugs Made In America Acquisition Corp. Units (2025–2025)

Year-by-year earnings quality comparison for Drugs Made In America Acquisition Corp. Units. For live market cap and the full company financial profile, see Drugs Made In America Acquisition Corp. stock valuation.

Year Quality Index Operating CF (USD) Net Income YoY Change
2025 -0.14x $-539.19K $3.97 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.